

# Involvement of PKC $\epsilon$ in Cardioprotection Induced by Adaptation to Chronic Continuous Hypoxia

K. HOLZEROVÁ<sup>1</sup>, M. HLAVÁČKOVÁ<sup>1,3</sup>, J. ŽURMANOVÁ<sup>2</sup>, G. BORCHERT<sup>3</sup>,  
J. NECKÁŘ<sup>3</sup>, F. KOLÁŘ<sup>3</sup>, F. NOVÁK<sup>1</sup>, O. NOVÁKOVÁ<sup>1</sup>

<sup>1</sup>Department of Cell Biology and <sup>2</sup>Department of Physiology, Faculty of Science, Charles University in Prague, <sup>3</sup>Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic

Received June 30, 2014

Accepted July 29, 2014

On-line October 15, 2014

## Summary

Continuous normobaric hypoxia (CNH) renders the heart more tolerant to acute ischemia/reperfusion injury. Protein kinase C (PKC) is an important component of the protective signaling pathway, but the contribution of individual PKC isoforms under different hypoxic conditions is poorly understood. The aim of this study was to analyze the expression of PKC $\epsilon$  after the adaptation to CNH and to clarify its role in increased cardiac ischemic tolerance with the use of PKC $\epsilon$  inhibitory peptide KP-1633. Adult male Wistar rats were exposed to CNH (10 % O<sub>2</sub>, 3 weeks) or kept under normoxic conditions. The protein level of PKC $\epsilon$  and its phosphorylated form was analyzed by Western blot in homogenate, cytosolic and particulate fractions; the expression of PKC $\epsilon$  mRNA was measured by RT-PCR. The effect of KP-1633 on cell viability and lactate dehydrogenase (LDH) release was analyzed after 25-min metabolic inhibition followed by 30-min re-energization in freshly isolated left ventricular myocytes. Adaptation to CNH increased myocardial PKC $\epsilon$  at protein and mRNA levels. The application of KP-1633 blunted the hypoxia-induced salutary effects on cell viability and LDH release, while control peptide KP-1723 had no effect. This study indicates that PKC $\epsilon$  is involved in the cardioprotective mechanism induced by CNH.

## Key words

Chronic hypoxia • Cardioprotection • Ventricular myocytes • Protein kinase C • PKC $\epsilon$  inhibitory peptide KP-1633

## Corresponding author

M. Hlaváčková, Department of Developmental Cardiology, Institute of Physiology, Czech Academy of Sciences, Videnska 1083, 142 20 Prague 4, Czech Republic.  
E-mail: [marketa.hlavackova@fgu.cas.cz](mailto:marketa.hlavackova@fgu.cas.cz)

## Introduction

The resistance of the heart to ischemia/reperfusion (I/R) injury can be increased by many acute and chronic stimuli such as various forms of preconditioning (Yellon and Downey 2003), postconditioning (Ovize *et al.* 2010), exercise training (Powers *et al.* 2008), caloric restriction (Shinmura *et al.* 2005) or exposure to chronic hypoxia (Kolar and Ostadal 2004). A number of studies have shown repeatedly that chronic hypoxia renders the heart more tolerant to deleterious ischemia followed by reperfusion that was manifested by decreased infarct size (Neckar *et al.* 2002a, b), lower incidence of ventricular arrhythmias (Asemu *et al.* 2000, Neckar *et al.* 2002a) and better recovery of cardiac contractile function (Neckar *et al.* 2002b, Wang *et al.* 2011, Xie *et al.* 2005). Despite the fact that hypoxia-induced cardioprotection has been known for many decades and its elucidation may have potential therapeutic repercussions, the complex mechanism underlying this form of a sustained protective phenotype is still a matter of debate. Among many components of protective signaling cascades stimulated by chronic hypoxia, various protein kinases such as protein kinase A

(Xie *et al.* 2005, Yeung *et al.* 2007), phosphatidylinositol 3-kinase/Akt (Milano *et al.* 2013, Ravingerova *et al.* 2007, Wang *et al.* 2011), glycogen synthase kinase-3 $\beta$  (McCarthy *et al.* 2011), Ca<sup>2+</sup>/calmodulin-dependent protein kinase II (Xie *et al.* 2004, Yu *et al.* 2009), p38-mitogen-activated protein kinase and c-Jun NH<sub>2</sub>-terminal kinase (Rafiee *et al.* 2002) and last but not least protein kinase C (PKC) (Ding *et al.* 2004, Li *et al.* 2007, Neckar *et al.* 2005, Rafiee *et al.* 2002, Wang *et al.* 2011, Yeung *et al.* 2007) have been shown to play a role.

PKC is a family of serine/threonine kinases that are important components in processes of cellular signaling. PKC includes several isoforms usually divided according to structure and requirement for second messengers. The three groups are as follows: a) classical (isoforms  $\alpha$ ,  $\beta$ I,  $\beta$ II and  $\gamma$ ), b) novel (isoforms  $\delta$ ,  $\epsilon$ ,  $\eta$  and  $\theta$ ) and c) atypical (isoforms  $\zeta$  and  $\iota/\lambda$ ) (Steinberg 2008). The discovery of general PKC inhibitors (chelerythrine, calphostin C) helped to reveal the essential role of PKC in the mechanism of hypoxia-induced cardioprotection as administration of these inhibitors abolished the protective phenotype (Ding *et al.* 2004, Neckar *et al.* 2005, Rafiee *et al.* 2002). The most frequently mentioned is the novel PKC isoform PKC $\epsilon$ , but its involvement in cardioprotection induced by chronic hypoxia still remains to be clarified (Ding *et al.* 2004, Hlavackova *et al.* 2007, Rafiee *et al.* 2002). However, the specificity of various inhibitors for individual PKC isoforms has been often questioned (Soltoff 2007). This was the case until a PKC $\epsilon$ -specific inhibitory peptide was synthesized by the Mochly-Rosen group which provided a powerful tool to elucidate the role of this isoform in ischemic preconditioning (Gray *et al.* 1997, Johnson *et al.* 1996).

It needs to be mentioned that the expression and activation of PKC isoforms associated with increased myocardial I/R resistance depends on the concrete model and regimen of chronic hypoxia. This complicates the interpretation of diverse results gained in individual studies (Ding *et al.* 2004, Neckar *et al.* 2005, Uenoyama *et al.* 2010). Recently, we have shown that adaptation of rats to continuous normobaric hypoxia (CNH) reduces the size of myocardial infarction induced by acute I/R (Maslov *et al.* 2013, Neckar *et al.* 2013). The aim of this study was to analyze the effect of CNH on myocardial expression of PKC $\epsilon$  and to examine its involvement in the protective mechanism using PKC $\epsilon$  inhibitory peptide KP-1633 and its inactive (scrambled) form KP-1723 (Mochly-Rosen 1995, Souroujon and Mochly-Rosen 1998).

## Methods

### Animals

Adult male Wistar rats (322 $\pm$ 11 g body weight) were exposed to CNH (inspired O<sub>2</sub> fraction: 0.1) in a normobaric chamber equipped with hypoxic generators (Everest Summit, Hypoxico Inc., NY, USA) for 3 weeks. The control group of animals was kept under normoxic conditions (inspired O<sub>2</sub> fraction: 0.21). All animals had free access to water and a standard laboratory diet and were housed with 12 hours light/12 hours dark cycle. They were killed by cervical dislocation 24 h after the hypoxic exposure, the hearts were removed and either used for cell isolation (method see below) or washed in cold saline (0 °C) and dissected into right and left free ventricular walls and septum. All samples were frozen in liquid nitrogen until use. The experiments were performed in accordance with the *Guide for the Care and Use of Laboratory Animals* published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and were approved by the Ethics Committee of the Institute of Physiology, Czech Academy of Sciences.

### Gene expression determined by Real-Time PCR

Total cellular RNA was extracted from each left ventricle (LV) sample using the Trizol Reagent (Invitrogen, Carlsbad, CA, USA). One microgram of total RNA was converted to cDNA using the RevertAid<sup>TM</sup> H Minus First Strand cDNA Synthesis Kit (Fermentas UAB, Vilnius, Lithuania) with oligo(dT) primers. Real-Time PCR was performed on a Light Cycler 480 (Roche Applied Science, Penzberg, Germany) using Light Cycler 480 Probes Master according to the manufacturer's protocol. Following specific primers together with Mono-Color Hydrolysis Probes were designed by the Universal Probe Library Assay Design Center:

PKC $\epsilon$  (F): *aaacacccttatctaacccaactct*,

PKC $\epsilon$  (R): *catattccatgacgaagaagagc*, #38,

HPRT1 (F): *gaccggttctgtcatgtcg*,

HPRT1 (R): *acctggttcatcatcaataacac*, #95.

The level of analyzed transcripts was normalized to the level of the reference gene hypoxanthine-guanine phosphoribosyltransferase 1 (HPRT1) gene transcript (Bohuslavova *et al.* 2010) according to Pfaffl (2001). For more details see Waskova-Arnostova *et al.* (2013).

### Tissue fractionation and Western blot analysis

LV samples were pulverized to fine powder with liquid nitrogen, dissolved in ice-cold homogenization

buffer (12.5 mM Tris-HCl (pH 7.4), 250 mM sucrose, 2.5 mM EGTA, 1 mM EDTA, 100 mM NaF, 0.3 mM phenylmethylsulfonyl fluoride, 6 mM  $\beta$ -mercaptoethanol, 10 mM glycerol-3-phosphate, 0.2 mM leupeptin, 0.02 mM aprotinin and 0.1 mM sodium orthovanadate) and homogenized by Potter-Elvehjem homogenizer at 4 °C. The part of the homogenate was centrifuged at  $100,000 \times g$  for 90 min to obtain the pellet of particulate fraction and cytosolic fraction (Kolar *et al.* 2007). The other part of the homogenate and the pellet of the particulate fraction were resuspended in homogenization buffer containing 1 % Triton X-100, held on ice for 60 min, with occasionally mixing, and then centrifuged at  $100,000 \times g$  for 90 min. Resulting supernatants were used for Western blot analyses. The protein concentration of individual samples was determined using the Bradford method (Bradford 1976).

Samples were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis using 10 % bis-acrylamide gel. Resolved proteins were transferred to a nitrocellulose membrane (Amersham Biosciences, Freiburg, Germany). Membranes were incubated with primary antibodies against PKC $\epsilon$  (Sigma-Aldrich, St. Louis, MO, USA), phosphorylated PKC $\epsilon$  (Upstate, Billerica, MA, USA), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and actin (Santa Cruz Biotechnology, Inc.). Horseradish peroxidase-conjugated anti-rabbit (Sigma-Aldrich) and anti-goat IgGs (Santa Cruz Biotechnology, Inc.) were used as secondary antibodies. Bands were visualized by enhanced chemiluminescence and quantified using ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA). In order to ensure the specificity of immunoreactive proteins, blocking was performed with immunizing peptides and rat brain homogenate was used as a positive control. GAPDH and actin were used as internal loading controls. The results were normalized to total protein amount.

#### *Isolation of cardiomyocytes*

Cardiomyocytes were isolated as previously described (Borchert *et al.* 2011). The rats were heparinized and killed by cervical dislocation. The hearts were perfused with Tyrode solution at 37 °C under constant flow (10 ml/min) for 5 min, followed by perfusion with Ca<sup>2+</sup>-free Tyrode for 8 min. Tissue digestion was initiated by adding 14000 U collagenase (Yakult, Tokyo, Japan) and 7 mg protease type XIV


(Sigma-Aldrich) into 30 ml of Ca<sup>2+</sup>-free Tyrode containing 50 mg BSA. All solutions were gassed with 100 % O<sub>2</sub>. After 12-15 min, the collagenase-protease cocktail was washed out by 10-min perfusion with Ca<sup>2+</sup>-free Tyrode. Myocytes isolated from the left ventricle (LVM) were dispersed mechanically and then filtered through a nylon mesh to remove non-dissociated tissue. LVM solutions were adjusted to the same cell density, transferred to culture medium (50 % Dulbecco's modified Eagle's medium and 50 % Nutrient Mixture F12HAM, containing 0.2 % BSA, 100 U/ml penicillin and 100 mg/ml streptomycin) and kept in a CO<sub>2</sub> incubator (95 % air, 5 % CO<sub>2</sub>, 28 °C) for a 1-h stabilization period.

#### *Assessment of cell viability with SYTOX Green*

The dose-response of LVM viability to the TAT-conjugated PKC $\epsilon$  inhibitory peptide KP-1633 and control peptide KP-1723 (scrambled amino acid sequence) obtained from KAI Pharmaceuticals, Inc. (South San Francisco, CA, USA) (Mochly-Rosen 1995, Souroujon and Mochly-Rosen 1998) was determined. Having considered the effective concentrations of the KP-1633 resembling peptide  $\epsilon$ V1-2 used in other studies (Chen *et al.* 1999), the concentrations of 0.1, 1, 5, 10 and 50  $\mu$ M KP-1633 and KP-1723 were tested. The percentage of living cells compared to the untreated control cells was assessed with SYTOX Green nucleic acid stain (S7020) (Invitrogen-Molecular Probes, Eugene, OR, USA) at the beginning of the experiment (after stabilization) and after 2, 4 and 20 h. The fluorescence signal of SYTOX Green, which is proportional to the number of dead cells (Hofgaard *et al.* 2006), was measured at an excitation wavelength of 490 nm and emission wavelength of 520 nm using a Synergy™ HT Multi-Detection Microplate Reader (BioTek, Winooski, VT, USA). Decreasing viability of LVM was already observed after 4-h incubation with 10  $\mu$ M KP-1633 and after 2, 4 and 20-h incubation with 50  $\mu$ M KP-1723 (data not shown). Therefore, the 5  $\mu$ M concentration of peptides, which had no effect on the number of surviving cells during 20-h incubation, has been chosen for the following experiments.

#### *Simulated ischemia/reperfusion*

LVM isolated from hypoxic and normoxic rats were pre-treated for 15 min with KP-1633 or KP-1723 and subjected to 25 min of metabolic inhibition (MI) followed by 30 min of re-energization (MI/R). LVM from each treatment group were split into two parts of equal



**Fig. 1.** Effect of continuous normobaric hypoxia (CNH) on the protein levels of PKCε (A), P-PKCε (Ser 729) (B) and the ratio P-PKCε/PKCε (C) in the left ventricular myocardium. Representative Western blots of PKCε and P-PKCε (Ser 729) are shown. The rats were adapted to CNH or kept under normoxic (N) conditions. The amount of protein applied to the gel was 10 μg (homogenate), 15 μg (cytosolic fraction) and 5 μg (particulate fraction) for PKCε and 40 μg (homogenate), 50 μg (cytosolic fraction) and 40 μg (particulate fraction) for P-PKCε. GAPDH and actin were used as loading controls. Values are presented as mean ± SE (n=5/group); \* P<0.05.

volumes. Control cells were incubated in a normal Krebs solution and not exposed to MI/R. MI was induced by the modified Krebs solution (containing 1.5 mM NaCN and 20 mM 2-deoxyglucose instead of glucose). The re-energization was achieved by replacing the MI solution with the normal cell culture medium (the same medium was applied to control cells).

*Cell viability and lactate dehydrogenase release*

Cell viability and lactate dehydrogenase (LDH) release were analyzed at the beginning of the experiments (after stabilization), after MI (LDH release only) and after re-energization as previously described (Borchert *et al.* 2011). The number of viable (unstained) myocytes was determined by Trypan blue exclusion (Wu *et al.* 1999). 50-100 myocytes were counted in duplicates from 6-10 independent experiments. Viable myocytes were divided according to the cell length-to-width ratio as follows: rod-shaped myocytes (ratio > 3:1) and non-rod-shaped myocytes (ratio < 3:1). Viability after MI/R was expressed as a percentage of rod-shaped cells that survived the MI/R insult and normalized to the appropriate control group not exposed to MI/R. LDH release was measured spectrophotometrically (Buhl and Jackson 1978) using the LDH Liqui-UV kit (Stanbio, Boerne, TX, USA). LDH released during MI and during re-energization was normalized to total LDH content in the cells and expressed as a percentage of appropriate control group not exposed to MI/R.


*Statistical analysis*

All values are presented as means ± SE. The results were compared using t-test or One-way ANOVA with Bonferroni post hoc test when appropriate. A p-value < 0.05 was considered as statistically significant.


**Results**

The analysis of PKCε and its phosphorylated form (P-PKCε) after the adaptation to CNH was


performed in homogenate, cytosolic and particulate fractions. Figure 1A shows the hypoxia-induced increase of PKC $\epsilon$  protein level in the particulate fraction (by 15 %) compared to the normoxic group. The level of P-PKC $\epsilon$  as well as the ratio P-PKC $\epsilon$ /PKC $\epsilon$  were not affected significantly (Fig. 1B and 1C, respectively). The PKC $\epsilon$  mRNA level increased after the adaptation to CNH by 48 % compared to normoxic controls (Fig. 2).



**Fig. 2.** Effect of continuous normobaric hypoxia (CNH) on myocardial expression of PKC $\epsilon$  mRNA. Total mRNA was extracted from left ventricles of rats adapted to CNH or kept in normoxic (N) conditions. The values of mRNA were normalized to the reference gene HPRT1. Values are presented as mean  $\pm$  SE (n=5/group); \*  $P$ <0.05.



**Fig. 3.** Effect of the control peptide KP-1723 and the PKC $\epsilon$  inhibitory peptide KP-1633 on survival of left ventricular myocytes during acute metabolic inhibition and re-energization, expressed as a percentage of control values. The cells were isolated from rats adapted to continuous normobaric hypoxia (CNH) or from rats kept in normoxic (N) conditions. Values are presented as mean  $\pm$  SE (n=6-10/group); \*  $P$ <0.05.



**Fig. 4.** Effect of the control peptide KP-1723 and the PKC $\epsilon$  inhibitory peptide KP-1633 on lactate dehydrogenase (LDH) release from left ventricular myocytes during metabolic inhibition (A), during re-energization (B), and total release (C), expressed as a percentage of corresponding LDH release from control cells. The cells were isolated from rats adapted to continuous normobaric hypoxia (CNH) or from rats kept in normoxic (N) conditions. Values are presented as mean  $\pm$  SE (n=6-10/group); \*  $P$ <0.05.

Figure 3 shows the improved viability of LVM from the hypoxic group after MI/R. The pre-treatment of LVM with KP-1723 did not affect the salutary effect of CNH. However, the pre-treatment of LVM with PKC $\epsilon$  inhibitory peptide KP-1633 blunted the hypoxia-induced increase in the cell survival.

Figure 4, A-C, respectively, show the effect of KP-1723 and KP-1633 on LDH release from LVM during MI, during re-energization and total LDH release during MI/R, expressed as a percentage of appropriate control values. In the untreated hypoxic group, LDH release was attenuated during MI, during re-energization and during MI/R. The pre-treatment of hypoxic as well as normoxic LVM with KP-1723 did not affect the LDH release and the salutary effect of CNH was preserved. In contrast, the pre-treatment of LVM with KP-1633 abolished the hypoxia-induced attenuation of LDH release in the re-energization phase.

## Discussion

Recently, we demonstrated that the uninterrupted exposure of rats to CNH for 3 weeks improved myocardial resistance to acute ischemic injury. This was evidenced by reduced size of myocardial infarction induced by coronary artery occlusion/reperfusion in open-chest animals (Neckar *et al.* 2013) as well as by decreased LDH release and improved survival of isolated LVM subjected to simulated I/R (Borchert *et al.* 2011, Neckar *et al.* 2013). The present study shows that CNH increases PKC $\epsilon$  mRNA expression and protein level in the particulate fraction of LV myocardium. To study the involvement of PKC $\epsilon$  in CNH-induced cardioprotective mechanism, we used the PKC $\epsilon$ -specific inhibitory peptide KP-1633, which inhibits the association of activated PKC $\epsilon$  with its anchoring protein, receptor for activated C kinase 2 (RACK2 or  $\beta$ -COP) (Mackay and Mochly-Rosen 2001, Mochly-Rosen 1995, Souroujon and Mochly-Rosen 1998). The pre-treatment of LVM with KP-1633 completely abolished the CNH-induced salutary effects on cell survival and LDH release during re-energization without affecting cells isolated from the hearts of normoxic animals. This indicates that PKC $\epsilon$  is critically involved in the CNH-induced cardioprotective mechanism.

Our study corresponds with other reports emphasizing the involvement of PKC $\epsilon$  in chronic hypoxia-induced cardioprotection (Rafiee *et al.* 2002,

Wang *et al.* 2011). However, these studies used various hypoxic stimuli/regimens and the PKC $\epsilon$  involvement was determined in different ways (analysis of translocation, phosphorylation or the loss of cardioprotective phenotype after the PKC $\epsilon$  inhibition). Wang *et al.* (2011) perfused isolated rat hearts with PKC $\epsilon$ -specific inhibitory peptide  $\epsilon$ V1-2, which abolished both PKC $\epsilon$  translocation (activation) from cytosolic to particulate fractions and the improvement of postischemic recovery of LV contractile function induced by moderate intermittent hypobaric hypoxia ( $PO_2=11.2$  kPa, 4 h/day, 4 weeks). Similarly, the general PKC inhibitor chelerythrine suppressed PKC $\epsilon$  activation and eliminated the infarct size-limiting effect in the hearts of infant rabbits adapted to CNH (10 %  $O_2$ , 10 days) (Rafiee *et al.* 2002). Interestingly, the prenatal exposure to chronic hypoxia had an adverse effect on myocardial resistance to I/R injury that was associated with PKC $\epsilon$  downregulation. Adult offspring of rats exposed to CNH (10.5 %  $O_2$ ) during the last trimester of gestation exhibited decreased myocardial levels of PKC $\epsilon$  and its phosphorylated form together with impaired postischemic recovery of LV function and increased infarct size compared with controls (Xue and Zhang 2009). The same regimen of prenatal CNH led to PKC $\epsilon$  downregulation and abolished heat stress-mediated cardioprotection in the later adulthood (Li *et al.* 2004). In contrast, decreased myocardial PKC $\epsilon$  expression was observed in our previous experiments on adult rats adapted to severe intermittent hypobaric hypoxia ( $PO_2=8.5$  kPa, 8 h/day, 5 weeks), which is cardioprotective (Hlavackova *et al.* 2010, Kolar *et al.* 2007). However, a beneficial role of another novel PKC isoform, PKC $\delta$ , was identified using this hypoxic regimen as indicated by a negative correlation of infarct size with PKC $\delta$  protein level (Hlavackova *et al.* 2007) and by an attenuation of infarct size-limiting effect using the PKC $\delta$ -selective inhibitor rottlerin (Neckar *et al.* 2005). Therefore, the involvement of the various PKC isoforms in hypoxia-induced cardioprotection is likely dependent on the hypoxic regimen used.

Although the available data mostly support the involvement of PKC $\epsilon$  in chronic hypoxia-induced cardioprotection, the comparison of individual studies is difficult and does not allow an unequivocal conclusion. Apart from differences among normobaric, hypobaric, continuous and intermittent hypoxia regimens, the intensity and total duration of hypoxic stimulus as well as the frequency and duration of individual hypoxic bouts are highly variable among models used (Asemu *et al.*

2000, Kolar *et al.* 2007, Milano *et al.* 2013, Neckar *et al.* 2013, Zong *et al.* 2004) and are likely to significantly influence the impact on myocardial ischemic resistance and the role of individual PKC isoforms. It is still unclear which of these factors plays a decisive role in terms of cardioprotection. On the other hand, the investigation of different modes of chronic hypoxic exposure has its importance, because the human heart also can be exposed to the various hypoxic conditions. This may occur either naturally (e.g. during prenatal period or living at high altitude) or under disease states (cyanotic congenital heart defects, chronic obstructive lung disease, ischemic heart disease, sleep apnea etc.) (Ostadal and Kolar 2007). Apart from different hypoxic modes, other factors need to be considered, such as gender differences (Ostadal *et al.* 1984, Xue and Zhang 2009), age of animals (La Padula and Costa 2005, Ostadalova *et al.* 2002), nutrition (Hlavackova *et al.* 2007) or animal species used (Manukhina *et al.* 2013, Wauthy *et al.* 2004, Zong *et al.* 2004). It is also important to take into account which part of the heart is analyzed, as marked differences exist in the effect of chronic hypoxia on PKC expression between right and left ventricles (Uenoyama *et al.* 2010).

The precise mechanism by which PKC $\epsilon$  activation exerts its protective effect is not fully understood. To date, several studies, mostly on preconditioning, identified many PKC $\epsilon$  target proteins that may play a role in cardioprotection. It has been demonstrated that PKC $\epsilon$ -mediated cardioprotection is linked to phosphorylation of connexin 43 (Doble *et al.* 2000, Jeyaraman *et al.* 2012), which among the other effects influences the gap junctional intercellular communication and thereby may prevent the spreading of injury during I/R. PKC $\epsilon$  also activates aldehyde dehydrogenase-2, which metabolizes toxic aldehydes formed during I/R (Budás *et al.* 2010). In addition, PKC $\epsilon$  may play an anti-apoptotic role by inhibition of pro-apoptotic Bcl-2 associated death domain protein (BAD) *via* its phosphorylation (Baines *et al.* 2002). It has been shown that an interaction of PKC $\epsilon$  with cytochrome *c* oxidase subunit IV improved cytochrome *c* oxidase activity in preconditioned rat myocardium (Guo *et al.* 2007). Interestingly, PKC $\epsilon$ , or more precisely yin/yang

effect of both PKC $\epsilon$  and PKC $\delta$  was also shown to inhibit and stimulate pyruvate dehydrogenase complex, respectively, and may thus play an important role in the maintenance of energy homeostasis in mitochondria (Gong *et al.* 2012). Another molecule which should not be omitted in connection with the mechanism of cardioprotection is nitric oxide (Ding *et al.* 2005), a direct activator of PKC $\epsilon$  (Balafanova *et al.* 2002). PKC $\epsilon$ -Akt-eNOS signaling modules were identified as critical signaling elements during PKC $\epsilon$ -induced cardiac protection (Zhang *et al.* 2005). The association of PKC $\epsilon$  and eNOS might thus represent a positive-feedback loop by which PKC $\epsilon$  activity can be modulated. PKC $\epsilon$  also phosphorylates glycogen synthase kinase-3 $\beta$  (Terashima *et al.* 2010) resulting in decreased mitochondrial permeability transition pore opening and improved resistance to myocardial infarction (Juhászova *et al.* 2004, 2009). The involvement of reactive oxygen species, PKC $\epsilon$  and glycogen synthase kinase-3 $\beta$  phosphorylation was observed also in cardioprotection induced by adaptation to moderate intermittent hypobaric hypoxia (PO<sub>2</sub>=11.2 kPa, 4 h/day, 4 weeks) (Wang *et al.* 2011).

In conclusion, adaptation of rats to CNH increased myocardial expression of PKC $\epsilon$  and protected isolated ventricular myocytes against injury caused by simulated I/R. The salutary effects of CNH were abolished by PKC $\epsilon$ -specific inhibitory peptide KP-1633, indicating the involvement of this PKC isoform in the cardioprotective mechanism.

### Conflict of Interest

There is no conflict of interest.

### Acknowledgements

We are grateful to KAI Pharmaceuticals, Inc. for providing us with KP-1633 and KP-1723 peptides. We thank Jana Vašinová for excellent technical assistance. This work was supported by the Czech Science Foundation (grants 303/12/1162 and 13-10267S), the Grant Agency of the Charles University in Prague (66310 and 161110), the UNCE-204013 and the Charles University grant SVV 260083.

### References

ASEMU G, NECKAR J, SZARSOZI O, PAPOUSEK F, OSTADAL B, KOLAR F: Effects of adaptation to intermittent high altitude hypoxia on ischemic ventricular arrhythmias in rats. *Physiol Res* 49: 597-606, 2000.

- BAINES CP, ZHANG J, WANG GW, ZHENG YT, XIU JX, CARDWELL EM, BOLLI R, PING P: Mitochondrial PKC $\epsilon$  and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKC $\epsilon$ -MAPK interactions and differential MAPK activation in PKC $\epsilon$ -induced cardioprotection. *Circ Res* **90**: 390-397, 2002.
- BALAFANOVA Z, BOLLI R, ZHANG J, ZHENG Y, PASS JM, BHATNAGAR A, TANG XL, WANG O, CARDWELL E, PING P: Nitric oxide (NO) induces nitration of protein kinase C $\epsilon$  (PKC $\epsilon$ ), facilitating PKC $\epsilon$  translocation via enhanced PKC $\epsilon$ -RACK2 interactions: a novel mechanism of no-triggered activation of PKC $\epsilon$ . *J Biol Chem* **277**: 15021-15027, 2002.
- BOHUSLAVOVA R, KOLAR F, KUTHANOVA L, NECKAR J, TICHOPAD A, PAVLINKOVA G: Gene expression profiling of sex differences in HIF1-dependent adaptive cardiac responses to chronic hypoxia. *J Appl Physiol* **109**: 1195-1202, 2010.
- BORCHERT GH, YANG C, KOLAR F: Mitochondrial BK $_{Ca}$  channels contribute to protection of cardiomyocytes isolated from chronically hypoxic rats. *Am J Physiol Heart Circ Physiol* **300**: H507-H513, 2011.
- BRADFORD MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* **72**: 248-254, 1976.
- BUDAS GR, DISATNIK MH, CHEN CH, MOCHLY-ROSEN D: Activation of aldehyde dehydrogenase 2 (ALDH2) confers cardioprotection in protein kinase C epsilon (PKC $\epsilon$ ) knockout mice. *J Mol Cell Cardiol* **48**: 757-764, 2010.
- BUHL SN, JACKSON KY: Optimal conditions and comparison of lactate dehydrogenase catalysis of the lactate-to-pyruvate and pyruvate-to-lactate reactions in human serum at 25, 30, and 37 °C. *Clin Chem* **24**: 828-831, 1978.
- CHEN CH, GRAY MO, MOCHLY-ROSEN D: Cardioprotection from ischemia by a brief exposure to physiological levels of ethanol: role of epsilon protein kinase C. *Proc Natl Acad Sci USA* **96**: 12784-12789, 1999.
- DING HL, ZHU HF, DONG JW, ZHU WZ, ZHOU ZN: Intermittent hypoxia protects the rat heart against ischemia/reperfusion injury by activating protein kinase C. *Life Sci* **75**: 2587-2603, 2004.
- DING HL, ZHU HF, DONG JW, ZHU WZ, YANG WW, YANG HT, ZHOU ZN: Inducible nitric oxide synthase contributes to intermittent hypoxia against ischemia/reperfusion injury. *Acta Pharmacol Sin* **26**: 315-322, 2005.
- DOBLE BW, PING P, KARDAMI E: The  $\epsilon$  subtype of protein kinase C is required for cardiomyocyte connexin-43 phosphorylation. *Circ Res* **86**: 293-301, 2000.
- GONG J, HOYOS B, ACIN-PEREZ R, VINOGRADOV V, SHABROVA E, ZHAO F, LEITGES M, FISCHMAN D, MANFREDI G, HAMMERLING U: Two protein kinase C isoforms,  $\delta$  and  $\epsilon$ , regulate energy homeostasis in mitochondria by transmitting opposing signals to the pyruvate dehydrogenase complex. *Faseb J* **26**: 3537-3549, 2012.
- GRAY MO, KARLINER JS, MOCHLY-ROSEN D: A selective  $\epsilon$ -protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death. *J Biol Chem* **272**: 30945-30951, 1997.
- GUO D, NGUYEN T, OGBI M, TAWFIK H, MA G, YU Q, CALDWELL RW, JOHNSON JA: Protein kinase C- $\epsilon$  coimmunoprecipitates with cytochrome oxidase subunit IV and is associated with improved cytochrome-c oxidase activity and cardioprotection. *Am J Physiol Heart Circ Physiol* **293**: H2219-H2230, 2007.
- HLAVACKOVA M, NECKAR J, JEZKOVA J, BALKOVA P, STANKOVA B, NOVAKOVA O, KOLAR F, NOVAK F: Dietary polyunsaturated fatty acids alter myocardial protein kinase C expression and affect cardioprotection induced by chronic hypoxia. *Exp Biol Med (Maywood)* **232**: 823-832, 2007.
- HLAVACKOVA M, KOZICHOVA K, NECKAR J, KOLAR F, MUSTERS RJ, NOVAK F, NOVAKOVA O: Up-regulation and redistribution of protein kinase C- $\delta$  in chronically hypoxic heart. *Mol Cell Biochem* **345**: 271-282, 2010.
- HOFGAARD JP, SIGURDARDOTTIR KS, TREIMAN M: Protection by 6-aminonicotinamide against oxidative stress in cardiac cells. *Pharmacol Res* **54**: 303-310, 2006.
- JEYARAMAN MM, SRISAKULDEE W, NICKEL BE, KARDAMI E: Connexin43 phosphorylation and cytoprotection in the heart. *Biochim Biophys Acta* **1818**: 2009-2013, 2012.
- JOHNSON JA, GRAY MO, CHEN CH, MOCHLY-ROSEN D: A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function. *J Biol Chem* **271**: 24962-24966, 1996.

- JUHASZOVA M, ZOROV DB, KIM SH, PEPE S, FU Q, FISHBEIN KW, ZIMAN BD, WANG S, YTREHUS K, ANTOS CL, OLSON EN, SOLLOTT SJ: Glycogen synthase kinase-3 $\beta$  mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. *J Clin Invest* **113**: 1535-1549, 2004.
- JUHASZOVA M, ZOROV DB, YANIV Y, NUSS HB, WANG S, SOLLOTT SJ: Role of glycogen synthase kinase-3 $\beta$  in cardioprotection. *Circ Res* **104**: 1240-1252, 2009.
- KOLAR F, OSTADAL B: Molecular mechanisms of cardiac protection by adaptation to chronic hypoxia. *Physiol Res* **53** (Suppl 1): S3-S13, 2004.
- KOLAR F, JEZKOVA J, BALKOVA P, BREH J, NECKAR J, NOVAK F, NOVAKOVA O, TOMASOVA H, SRBOVA M, OSTADAL B, WILHELM J, HERGET J: Role of oxidative stress in PKC- $\delta$  upregulation and cardioprotection induced by chronic intermittent hypoxia. *Am J Physiol Heart Circ Physiol* **292**: H224-H230, 2007.
- LA PADULA P, COSTA LE: Effect of sustained hypobaric hypoxia during maturation and aging on rat myocardium. I. Mechanical activity. *J Appl Physiol* **98**: 2363-2369, 2005.
- LI G, BAE S, ZHANG L: Effect of prenatal hypoxia on heat stress-mediated cardioprotection in adult rat heart. *Am J Physiol* **286**: H1712-H1719, 2004.
- LI J, ZHANG H, ZHU WZ, YU Z, GUO A, YANG HT, ZHOU ZN: Preservation of the pHi during ischemia via PKC by intermittent hypoxia. *Biochem Biophys Res Commun* **356**: 329-333, 2007.
- MACKAY K, MOCHLY-ROSEN D: Localization, anchoring, and functions of protein kinase C isozymes in the heart. *J Mol Cell Cardiol* **33**: 1301-1307, 2001.
- MANUKHINA EB, BELKINA LM, TEREKHINA OL, ABRAMOCHKIN DV, SMIRNOVA EA, BUDANOVA OP, MALLETT RT, DOWNEY HF: Normobaric, intermittent hypoxia conditioning is cardio- and vasoprotective in rats. *Exp Biol Med (Maywood)* **238**: 1413-1420, 2013.
- MASLOV LN, NARYZHNAIA NV, TSIBULNIKOV SY, KOLAR F, ZHANG Y, WANG H, GUSAKOVA AM, LISHMANOV YB: Role of endogenous opioid peptides in the infarct size-limiting effect of adaptation to chronic continuous hypoxia. *Life Sci* **93**: 373-379, 2013.
- MCCARTHY J, LOCHNER A, OPIE LH, SACK MN, ESSOP MF: PKC $\epsilon$  promotes cardiac mitochondrial and metabolic adaptation to chronic hypobaric hypoxia by GSK3 $\beta$  inhibition. *J Cell Physiol* **226**: 2457-2468, 2011.
- MILANO G, ABRUZZO PM, BOLOTTA A, MARINI M, TERRANEO L, RAVARA B, GORZA L, VITADELLO M, BURATTINI S, CURZI D, FALCIERI E, VON SEGESSER LK, SAMAJA M: Impact of the phosphatidylinositol 3-kinase signaling pathway on the cardioprotection induced by intermittent hypoxia. *PLoS One* **8**: e76659, 2013.
- MOCHLY-ROSEN D: Localization of protein kinases by anchoring proteins: a theme in signal transduction. *Science* **268**: 247-251, 1995.
- NECKAR J, PAPOUSEK F, NOVAKOVA O, OSTADAL B, KOLAR F: Cardioprotective effects of chronic hypoxia and ischaemic preconditioning are not additive. *Basic Res Cardiol* **97**: 161-167, 2002a.
- NECKAR J, SZARSZOI O, KOTEN L, PAPOUSEK F, OSTADAL B, GROVER GJ, KOLAR F: Effects of mitochondrial K<sub>ATP</sub> modulators on cardioprotection induced by chronic high altitude hypoxia in rats. *Cardiovasc Res* **55**: 567-575, 2002b.
- NECKAR J, MARKOVA I, NOVAK F, NOVAKOVA O, SZARSZOI O, OSTADAL B, KOLAR F: Increased expression and altered subcellular distribution of PKC- $\delta$  in chronically hypoxic rat myocardium: involvement in cardioprotection. *Am J Physiol Heart Circ Physiol* **288**: H1566-H1572, 2005.
- NECKAR J, BORCHERT GH, HLOUSKOVA P, MICOVA P, NOVAKOVA O, NOVAK F, HROCH M, PAPOUSEK F, OSTADAL B, KOLAR F: Brief daily episode of normoxia inhibits cardioprotection conferred by chronic continuous hypoxia. Role of oxidative stress and BK<sub>Ca</sub> channels. *Curr Pharm Des* **19**: 6880-6889, 2013.
- OSTADAL B, KOLAR F: Cardiac adaptation to chronic high-altitude hypoxia: beneficial and adverse effects. *Respir Physiol Neurobiol* **158**: 224-236, 2007.
- OSTADAL B, PROCHAZKA J, PELOUCH V, URBANOVA D, WIDIMSKY J: Comparison of cardiopulmonary responses of male and female rats to intermittent high altitude hypoxia. *Physiol Bohemoslov* **33**: 129-138, 1984.

- OSTADALOVA I, OSTADAL B, JARKOVSKA D, KOLAR F: Ischemic preconditioning in chronically hypoxic neonatal rat heart. *Pediatr Res* **52**: 561-567, 2002.
- OVIZE M, BAXTER GF, DI LISA F, FERDINANDY P, GARCIA-DORADO D, HAUSENLOY DJ, HEUSCH G, VINTEN-JOHANSEN J, YELLON DM, SCHULZ R: Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. *Cardiovasc Res* **87**: 406-423, 2010.
- PFAFFL MW: A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res* **29**: e45, 2001.
- POWERS SK, QUINDRY JC, KAVAZIS AN: Exercise-induced cardioprotection against myocardial ischemia-reperfusion injury. *Free Radic Biol Med* **44**: 193-201, 2008.
- RAFIEE P, SHI Y, KONG X, PRITCHARD KA Jr, TWEDDELL JS, LITWIN SB, MUSSATTO K, JAQUISS RD, SU J, BAKER JE: Activation of protein kinases in chronically hypoxic infant human and rabbit hearts: role in cardioprotection. *Circulation* **106**: 239-245, 2002.
- RAVINGEROVA T, MATEJIKOVA J, NECKAR J, ANDELOVA E, KOLAR F: Differential role of PI3K/Akt pathway in the infarct size limitation and antiarrhythmic protection in the rat heart. *Mol Cell Biochem* **297**: 111-120, 2007.
- SHINMURA K, TAMAKI K, BOLLI R: Short-term caloric restriction improves ischemic tolerance independent of opening of ATP-sensitive K<sup>+</sup> channels in both young and aged hearts. *J Mol Cell Cardiol* **39**: 285-296, 2005.
- SOLTOFF SP: Rottlerin: an inappropriate and ineffective inhibitor of PKC $\delta$ . *Trends Pharmacol Sci* **28**: 453-458, 2007.
- SOUROUJON MC, MOCHLY-ROSEN D: Peptide modulators of protein-protein interactions in intracellular signaling. *Nat Biotechnol* **16**: 919-924, 1998.
- STEINBERG SF: Structural basis of protein kinase C isoform function. *Physiol Rev* **88**: 1341-1378, 2008.
- TERASHIMA Y, SATO T, YANO T, MAAS O, ITOH T, MIKI T, TANNO M, KUNO A, SHIMAMOTO K, MIURA T: Roles of phospho-GSK-3 $\beta$  in myocardial protection afforded by activation of the mitochondrial K<sub>ATP</sub> channel. *J Mol Cell Cardiol* **49**: 762-770, 2010.
- UENOYAMA M, OGATA S, NAKANISHI K, KANAZAWA F, HIROI S, TOMINAGA S, SEO A, MATSUI T, KAWAI T, SUZUKI S: Protein kinase C mRNA and protein expressions in hypobaric hypoxia-induced cardiac hypertrophy in rats. *Acta Physiol (Oxf)* **198**: 431-440, 2010.
- WANG ZH, CHEN YX, ZHANG CM, WU L, YU Z, CAI XL, GUAN Y, ZHOU ZN, YANG HT: Intermittent hypobaric hypoxia improves postischemic recovery of myocardial contractile function via redox signaling during early reperfusion. *Am J Physiol Heart Circ Physiol* **301**: H1695-H1705, 2011.
- WASKOVA-ARNOSTOVA P, ELSNICOVA B, KASPAROVA D, SEBESTA O, NOVOTNY J, NECKAR J, KOLAR F, ZURMANOVA J: Right-to-left ventricular differences in the expression of mitochondrial hexokinase and phosphorylation of Akt. *Cell Physiol Biochem* **31**: 66-79, 2013.
- WAUTHY P, PAGNAMENTA A, VASSALLI F, NAEIJE R, BRIMIOULLE S: Right ventricular adaptation to pulmonary hypertension: an interspecies comparison. *Am J Physiol Heart Circ Physiol* **286**: H1441-H1447, 2004.
- WU S, LI HY, WONG TM: Cardioprotection of preconditioning by metabolic inhibition in the rat ventricular myocyte. Involvement of  $\kappa$ -opioid receptor. *Circ Res* **84**: 1388-1395, 1999.
- XIE Y, ZHU WZ, ZHU Y, CHEN L, ZHOU ZN, YANG HT: Intermittent high altitude hypoxia protects the heart against lethal Ca<sup>2+</sup> overload injury. *Life Sci* **76**: 559-572, 2004.
- XIE Y, ZHU Y, ZHU WZ, CHEN L, ZHOU ZN, YUAN WJ, YANG HT: Role of dual-site phospholamban phosphorylation in intermittent hypoxia-induced cardioprotection against ischemia-reperfusion injury. *Am J Physiol Heart Circ Physiol* **288**: H2594-H2602, 2005.
- XUE Q, ZHANG L: Prenatal hypoxia causes a sex-dependent increase in heart susceptibility to ischemia and reperfusion injury in adult male offspring: role of protein kinase C $\epsilon$ . *J Pharmacol Exp Ther* **330**: 624-632, 2009.
- YELLON DM, DOWNEY JM: Preconditioning the myocardium: from cellular physiology to clinical cardiology. *Physiol Rev* **83**: 1113-1151, 2003.

- YEUNG HM, KRAVTSOV GM, NG KM, WONG TM, FUNG ML: Chronic intermittent hypoxia alters Ca<sup>2+</sup> handling in rat cardiomyocytes by augmented Na<sup>+</sup>/Ca<sup>2+</sup> exchange and ryanodine receptor activities in ischemia-reperfusion. *Am J Physiol Cell Physiol* **292**: C2046-C2056, 2007.
- YU Z, WANG ZH, YANG HT: Calcium/calmodulin-dependent protein kinase II mediates cardioprotection of intermittent hypoxia against ischemic-reperfusion-induced cardiac dysfunction. *Am J Physiol Heart Circ Physiol* **297**: H735-H742, 2009.
- ZHANG J, BAINES CP, ZONG C, CARDWELL EM, WANG G, VONDRISKA TM, PING P: Functional proteomic analysis of a three-tier PKC $\epsilon$ -Akt-eNOS signaling module in cardiac protection. *Am J Physiol Heart Circ Physiol* **288**: H954-H961, 2005.
- ZONG P, SETTY S, SUN W, MARTINEZ R, TUNE JD, EHRENBURG IV, TKATCHOUK EN, MALLET RT, DOWNEY HF: Intermittent hypoxic training protects canine myocardium from infarction. *Exp Biol Med (Maywood)* **229**: 806-812, 2004.
-